case report aspiration during anesthesia semaglutide 2023 Are Serious Anesthesia Risks of Semaglutide and Other GLP-1 Agonists Under-Recognized? Case Reports of Retained Solid Gastric Contents in Patients Undergoing Anesthesia Ozempic users at higher risk

A compounding interest Going forward, the FDA will allow compounding of prescriptions specific to particular patients

Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and/or overweight: study protocol for a randomised, placebo-controlled clinical trial

Semaglutide, Ozempic & Wegovy: semaglutide is the GLP-1 receptor agonist peptide sold pharmaceutically under the brand names Ozempic and Wegovy (and orally as Rybelsus) by Novo Nordisk

Proposed evaluation strategies could encompass monitoring weight loss of a minimum of 5%, a serum ALT level decrease and a 20% LSM reduction at 612 months intervals

Patoulias D, Stavropoulos K, Imprialos K, et al